Pusan National University Yangsan Hospital is conducting the clinical trial Ice Plant (Mesembryanthemum Crystallinum) Extract in Patients With Impaired Fasting Glucose.
The investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects and tolerability of ice plant (Mesembryanthemum crystallinum) extract in patients with impaired fasting glucose for 12 weeks. It is planned to include 40 participants. The researchers expect to complete the study by December 31, 2022.
Patients with with fasting blood glucose of 100 mg/dL or more and less than 140 mg/dL may participate. There is a number of exclusion criteria, such as suffering from type 1 or type 2 diabetes, previous history of drugs that may affect blood glucose within 3 months, taking health functional food that can affect blood glucose within 1 month or health functional food can affect the interpretation of the results of this study, taking systemic steroids within 1 month, having lost in weight within the last 3 months, suffering form severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.) within the last 6 months), heart disease (angina pectoris, myocardial infarction, heart failure, arrhythmia that needs to be treated), or a malignant tumor, local or systemic inflammatory diseases, renal disease such as hereditary hyperlipidemia, acute/chronic renal failure, nephrotic syndrome. The complete list of the exlcusion criteria, as well as the location of the study can be found here: https://ichgcp.net/clinical-trials-registry/NCT05544825.